Log in
NYSE:ABBV

AbbVie Competitors

$80.67
+0.18 (+0.22 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$79.11
Now: $80.67
$81.37
50-Day Range
$80.49
MA: $87.03
$91.63
52-Week Range
$62.55
Now: $80.67
$101.28
Volume8.66 million shs
Average Volume9.65 million shs
Market Capitalization$142.37 billion
P/E Ratio17.16
Dividend Yield5.86%
Beta0.74

Competitors

AbbVie (NYSE:ABBV) Vs. JNJ, PFE, MRK, BMY, LLY, and ZTS

Should you be buying ABBV stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to AbbVie, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), and Zoetis (ZTS).

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Institutional and Insider Ownership

68.2% of AbbVie shares are owned by institutional investors. Comparatively, 67.4% of Johnson & Johnson shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

AbbVie has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares AbbVie and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie19.20%-628.57%14.66%
Johnson & Johnson21.01%35.10%13.69%

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.9%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 58 consecutive years.

Earnings & Valuation

This table compares AbbVie and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.28$7.88 billion$8.949.02
Johnson & Johnson$82.06 billion4.40$15.12 billion$8.6815.81

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for AbbVie and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie141402.68
Johnson & Johnson031002.77

AbbVie currently has a consensus target price of $108.7059, indicating a potential upside of 34.75%. Johnson & Johnson has a consensus target price of $166.0769, indicating a potential upside of 21.06%. Given AbbVie's higher possible upside, research analysts plainly believe AbbVie is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats AbbVie on 10 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for Pfizer and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08502.38
AbbVie141402.68

Pfizer currently has a consensus price target of $39.8692, indicating a potential upside of 13.01%. AbbVie has a consensus price target of $108.7059, indicating a potential upside of 34.75%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Pfizer.

Volatility and Risk

Pfizer has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.3%. AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Pfizer pays out 51.5% of its earnings in the form of a dividend. AbbVie pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Pfizer and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer28.80%25.11%9.52%
AbbVie19.20%-628.57%14.66%

Institutional and Insider Ownership

69.1% of Pfizer shares are held by institutional investors. Comparatively, 68.2% of AbbVie shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Pfizer and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.79$16.27 billion$2.9511.96
AbbVie$33.27 billion4.28$7.88 billion$8.949.02

Pfizer has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Pfizer on 11 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.2%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 1 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Valuation and Earnings

This table compares AbbVie and Merck & Co., Inc.'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.28$7.88 billion$8.949.02
Merck & Co., Inc.$46.84 billion4.10$9.84 billion$5.1914.62

Merck & Co., Inc. has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AbbVie has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AbbVie and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie141402.68
Merck & Co., Inc.021202.86

AbbVie currently has a consensus price target of $108.7059, indicating a potential upside of 34.75%. Merck & Co., Inc. has a consensus price target of $95.3571, indicating a potential upside of 25.65%. Given AbbVie's higher possible upside, research analysts clearly believe AbbVie is more favorable than Merck & Co., Inc..

Profitability

This table compares AbbVie and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie19.20%-628.57%14.66%
Merck & Co., Inc.22.20%52.94%16.50%

Insider & Institutional Ownership

68.2% of AbbVie shares are owned by institutional investors. Comparatively, 73.2% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats AbbVie on 10 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Insider & Institutional Ownership

68.2% of AbbVie shares are held by institutional investors. Comparatively, 72.6% of Bristol-Myers Squibb shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

AbbVie has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for AbbVie and Bristol-Myers Squibb, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie141402.68
Bristol-Myers Squibb071402.67

AbbVie presently has a consensus target price of $108.7059, indicating a potential upside of 34.75%. Bristol-Myers Squibb has a consensus target price of $78.1667, indicating a potential upside of 34.96%. Given Bristol-Myers Squibb's higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than AbbVie.

Profitability

This table compares AbbVie and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie19.20%-628.57%14.66%
Bristol-Myers Squibb-1.61%28.47%10.79%

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 3.1%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings and Valuation

This table compares AbbVie and Bristol-Myers Squibb's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.28$7.88 billion$8.949.02
Bristol-Myers Squibb$26.15 billion5.01$3.44 billion$4.6912.35

AbbVie has higher revenue and earnings than Bristol-Myers Squibb. AbbVie is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Bristol-Myers Squibb on 10 of the 16 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Dividends

Eli Lilly and pays an annual dividend of $2.96 per share and has a dividend yield of 2.2%. AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Eli Lilly and pays out 49.0% of its earnings in the form of a dividend. AbbVie pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 1 consecutive years.

Risk & Volatility

Eli Lilly and has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Insider & Institutional Ownership

76.4% of Eli Lilly and shares are owned by institutional investors. Comparatively, 68.2% of AbbVie shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Eli Lilly and and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.48%183.80%15.63%
AbbVie19.20%-628.57%14.66%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eli Lilly and and AbbVie, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and04912.79
AbbVie141402.68

Eli Lilly and presently has a consensus target price of $171.00, indicating a potential upside of 29.01%. AbbVie has a consensus target price of $108.7059, indicating a potential upside of 34.75%. Given AbbVie's higher probable upside, analysts plainly believe AbbVie is more favorable than Eli Lilly and.

Earnings and Valuation

This table compares Eli Lilly and and AbbVie's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion5.68$8.32 billion$6.0421.95
AbbVie$33.27 billion4.28$7.88 billion$8.949.02

Eli Lilly and has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats AbbVie on 10 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a summary of recent recommendations for Zoetis and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis09812.56
AbbVie141402.68

Zoetis currently has a consensus price target of $156.1538, suggesting a potential downside of 3.12%. AbbVie has a consensus price target of $108.7059, suggesting a potential upside of 34.75%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Zoetis.

Valuation & Earnings

This table compares Zoetis and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion12.23$1.50 billion$3.6444.28
AbbVie$33.27 billion4.28$7.88 billion$8.949.02

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Dividends

Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.9%. Zoetis pays out 22.0% of its earnings in the form of a dividend. AbbVie pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 1 consecutive years.

Risk and Volatility

Zoetis has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Profitability

This table compares Zoetis and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
AbbVie19.20%-628.57%14.66%

Institutional & Insider Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 68.2% of AbbVie shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zoetis beats AbbVie on 9 of the 17 factors compared between the two stocks.


AbbVie Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.3$137.19+0.9%$361.16 billion$82.06 billion21.57
Pfizer logo
PFE
Pfizer
2.9$35.28+0.5%$196.05 billion$51.75 billion14.00Earnings Announcement
Analyst Report
Insider Buying
Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.5$75.89+0.4%$191.94 billion$46.84 billion18.51Earnings Announcement
Analyst Report
Heavy News Reporting
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$57.92+0.3%$131.06 billion$26.15 billion-579.14Upcoming Earnings
Increase in Short Interest
Eli Lilly and logo
LLY
Eli Lilly and
2.2$132.55+0.9%$126.78 billion$22.32 billion21.52Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
1.8$161.19+1.6%$76.59 billion$6.26 billion47.83Upcoming Earnings
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
1.7$77.72+0.6%$16.05 billion$1.30 billion31.85Upcoming Earnings
Unusual Options Activity
Heavy News Reporting
Royalty Pharma logo
RPRX
Royalty Pharma
1.8$36.34+0.6%$13.30 billionN/A0.00
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$145.63+0.0%$8.08 billion$2.16 billion63.04Upcoming Earnings
Analyst Upgrade
Mylan logo
MYL
Mylan
1.8$14.37+0.5%$7.43 billion$11.50 billion27.11Upcoming Earnings
Analyst Report
Perrigo logo
PRGO
Perrigo
2.8$42.53+0.1%$5.80 billion$4.84 billion24.44Upcoming Earnings
Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$16.21+1.9%$2.90 billion$114.62 million-6.67Upcoming Earnings
Heavy News Reporting
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.4$53.12+2.0%$2.27 billion$421.03 million-212.48Earnings Announcement
Heavy News Reporting
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.8$17.16+0.2%$1.98 billion$306.49 million18.26Upcoming Earnings
Analyst Upgrade
Zogenix logo
ZGNX
Zogenix
1.6$21.32+4.3%$1.18 billion$3.65 million-2.24
Endo International logo
ENDP
Endo International
1.1$4.73+7.0%$1.09 billion$2.91 billion-6.76Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$18.35+3.5%$966.38 million$392.76 million8.30Upcoming Earnings
Omeros logo
OMER
Omeros
1.4$10.50+0.4%$572.44 million$111.81 million-5.12
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.4$14.99+0.5%$492.50 million$15.96 million-5.95Upcoming Earnings
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$3.12+1.0%$314.91 million$111.39 million62.40Upcoming Earnings
Lannett logo
LCI
Lannett
2.4$6.44+0.8%$259.02 million$545.74 million-7.40Upcoming Earnings
Analyst Upgrade
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$4.88+2.0%$221.49 million$16.54 million-1.63Upcoming Earnings
Heavy News Reporting
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.01+2.0%$45.57 million$47.53 million-9.41
VIVUS logo
VVUS
VIVUS
1.2$0.34+0.0%$5.99 million$69.76 million-0.12
This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.